Sham Mailankody, MD

Articles by Sham Mailankody, MD

Bispecific Antibodies in Relapsed/Refractory MM: Future Perspectives

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 26th 2023

Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.

Appropriate Patient Selection for Cevostamab in Relapsed/Refractory MM

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 26th 2023

Shared insight on possible real-world applications for FcRH5-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

Patient Case 3: Cevostamab in a Patient with MM who Progressed on Multiple Lines of Therapy

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 19th 2023

Centering discussion on the final patient case, experts review the case of a patient with relapsed/refractory multiple myeloma managed with FcRH5-targeting bispecific cevostamab.

Appropriate Patient Selection for Talquetamab in Relapsed/Refractory MM

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 19th 2023

Considerations for the integration of GPRC5-targeted therapy into the real-world treatment paradigm of relapsed/refractory multiple myeloma.

Patient Case 2: Managing Heavily Pre-Treated MM With Talquetamab

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 12th 2023

Switching focus to GPRC5-targeted bispecific antibody therapy, expert hematologist-oncologists review a patient case of relapsed/refractory MM managed with talquetamab.

BCMA-Targeting Bispecific Antibodies in RRMM: Managing ICANS and Infections

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 12th 2023

Closing out their module on BCMA-targeted therapy in relapsed/refractory MM, panelists highlight the optimal management of ICANS and infections.

BCMA-Targeting Bispecific Antibodies in RRMM: Optimal Management of CRS

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 5th 2023

Focused discussion from a panel of key opinion leaders on the presence and management of cytokine release syndrome alongside BCMA-targeted therapy in relapsed/refractory MM.

Selecting and Sequencing BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

January 5th 2023

Shared insight from expert hematologist-oncologists on the real-world application of teclistamab to improve the management of multiple myeloma.

Overview of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory MM

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

December 29th 2022

A broad perspective on the development of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Patient Case 1: Relapsed/Refractory MM Managed With Teclistamab

ByAjai Chari, MD,Krina K. Patel, MD,Alfred Garfall, MD,Sham Mailankody, MD

December 29th 2022

Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.

Future Perspectives: Treating Multiple Myeloma With Novel Regimens

BySaad Z. Usmani, MD, MBA, FACP,Urvi Shah, MD,Sham Mailankody, MD,Neha Korde, MD

February 15th 2022

An overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.

Sequencing Novel Therapies Into Multiple Myeloma Treatment Algorithms

BySaad Z. Usmani, MD, MBA, FACP,Sham Mailankody, MD,Neha Korde, MD,Urvi Shah, MD

February 15th 2022

Recommendations regarding best approaches to using novel therapies to treat multiple myeloma based on current drug approvals as well as new therapies in the pipeline.

Preferences for Managing Relapsed Multiple Myeloma

BySaad Z. Usmani, MD, MBA, FACP,Neha Korde, MD,Urvi Shah, MD,Sham Mailankody, MD

February 15th 2022

Treatment options available for an elderly man with multiple myeloma upon first relapse.

Minimal Residual Disease as a Biomarker in Multiple Myeloma

BySaad Z. Usmani, MD, MBA, FACP,Neha Korde, MD,Urvi Shah, MD,Sham Mailankody, MD

February 8th 2022

What needs to be investigated further before adopting MRD assessments for multiple myeloma into routine clinical practice.

Transplant-Ineligible Multiple Myeloma: Triplet vs Quadruplet Therapy

BySaad Z. Usmani, MD, MBA, FACP,Sham Mailankody, MD,Neha Korde, MD,Urvi Shah, MD

February 8th 2022

Considerations for selecting between a conventional front-line triplet regimen to manage a patient with high-risk multiple myeloma who is ineligible for transplant vs a new quadruplet regimen, as demonstrated in recent clinical trial data.